{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"2.470","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"468,172,600","primaryexch":"香港交易所","ric":"9939.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BMDWVN6","am":"5.64","iv":"","ew_strike":"","as":"2.370","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"2.360","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"0.850","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"童友之","underlying_ric":"9939.HK","hi52":"3.100","issuer_name":"開拓藥業有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日15:58","aum_date":"","lo":"2.360","mkt_cap":"1.11","f_aum_hkd":null,"ew_sub_per_to":"","ls":"2.380","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.100","aum":"","issued_shares_class_B":null,"vo":"2.35","secondary_listing_flag":false,"listing_date":"2020年5月22日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"開拓藥業有限公司 - B","nm_s":"開拓藥業－Ｂ","sym":"9939","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"開拓藥業有限公司是臨床階段新藥開發商。該公司產品致力於解決未滿足臨床需求的疾病領域，管線主要涵蓋皮科（如脫髮、痤瘡等）及腫瘤適應症。該公司在皮科領域有兩款核心藥物KX-826及GT20029。該公司在其他疾病領域包括轉移性去勢抗性前列腺癌（mCRPC）、肝癌、特發性肺纖維化、惡性血液疾病及多種實體腫瘤等。","op":"2.470","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>大新金融中心<br/>40樓","pc":"-4.03","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"2.480","isin":"KYG5273B1077","moneyness":""}},"qid":"1759074441640"}
